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Pimpinella anisum in the treatment 
of functional dyspepsia: A double-blind, 
randomized clinical trial
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Background: We aimed to evaluate the effects of Pimpinella anisum (anise) from Apiaceae family on relieving the symptoms of 
postprandial distress syndrome (PDS) in this double-blind randomized clinical trial. Materials and Methods: Totally, 107 patients 
attending the gastroenterology clinic, aged 18-65 years, diagnosed with PDS according to ROME III criteria and signed a written 
consent form were enrolled. They were randomized to receive either anise or placebo, blindly, for 4 weeks. Anise group included 
47 patients and received anise powders, 3 g after each meal (3 times/day). Control group involved 60 patients and received placebo 
powders (corn starch), 3 gafter each meal (3 times/day). The severity of Functional dyspepsia (FD) symptoms was assessed by FD 
severity scale. Assessments were done at baseline and by the end of weeks 2, 4 and 12. Mean scores of severity of FD symptoms 
and the frequency distribution of patients across the study period were compared. Results: The age, sex, body mass index, smoking 
history, and coffee drinking pattern of the intervention and control groups were not significantly different. Mean (standard deviation) 
total scores of FD severity scale before intervention in the anise and control groups were 10.6 (4.1) and 10.96 (4.1), respectively 
(P = 0.6). They were 7.04 (4.1) and 12.30 (4.3) by week 2, respectively (P = 0.0001), 2.44 (4.2) and 13.05 (5.2) by week 4, respectively 
(P = 0.0001), and 1.08 (3.8) and 13.30 (6.2) by week 12, respectively (P = 0.0001). Conclusion: This study showed the effectiveness of 
anise in relieving the symptoms of postpartum depression. The findings were consistent across the study period at weeks 2, 4 and 12.
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nervous system and visceral hypersensitivity.[32-37] 
Although the regular pharmacologic treatments for 
FD include antacids, kinetic-modifying agents, anti-H. 
pylori antibiotics, anxiolytics, and antidepressants, 
their benefits are limited in many cases and remained 
unsatisfactory.[38,39] That’s why the search for optimum 
treatment is continued, and alternative medicine has 
gained more and more popularity among the patients 
and even physicians. It has been estimated by World 
Health Organization that probably 80% of the population 
around the world may trust traditional medicine to meet 
their primary health care needs.[40] Unfortunately, there 
isn’t enough satisfactory evidence based on randomized 
clinical trials to demonstrate the efficacy and safety 
of the majority of herbal medicines. One of the herbs 
in the latter group used to treat patients in over 4000-
year history of Iranian medicine was Pimpinella anisum 
(Apiaceae).[41] Different therapeutic effects have been 
INTRODUCTION
Functional dyspepsia (FD) is a prevalent gastrointestinal 
(GI) disorder. Its prevalence is different in various 
populations and outpatient clinics.[1] The patients suffer 
from dyspepsia, but no pathologic lesion, or metabolic 
abnormality is identified.[2] They complain about 
epigastric pain/burning or upper abdomen postprandial 
discomforts. According to Rome III criteria, FD includes 
two main subtypes of epigastric pain syndrome and 
postprandial distress syndrome (PDS).[3,4] The latter 
involves patients with meal-related symptoms of 
bothersome postprandial fullness and early satiety. 
Its etiology is very complex and may include gastric 
dysmotility (delayed gastric emptying),[5-7] Helicobacter 
pylori infection,[8-12] local inflammations,[2,13-17] abnormal 
brain-gut interactions,[18-26] abnormal acid secretion,[27,28] 
genetic susceptibility,[29-31] imbalanced autonomic 
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reported for anise including antioxidant, antifungal,[42] 
antimicrobial,[43] analgesic,[44] anticonvulsant[45,46] and 
antispastic[47] properties. It also has many GI effects. 
For instance, anise implemented its antiulcer effects by 
inhibiting gastric mucosal damage.[48] The aromatic effects 
of anise have been effective in the palliation of nausea.[49] 
Its laxative property has been effective in the treatment of 
constipation.[50] The aim of current clinical trial was to assess 
the effects of anise fruit on patients with PDS.
MATERIALS AND METHODS
Study design
The current study was a double-blind, randomized clinical 
trial conducted in Isfahan University of Medical Sciences 
(IUMS). Patients attending Gastroenterology Clinic of the 
university hospital from August 2013 to March 2014 were 
evaluated. Totally, 180 patients were visited and assessed. 
Those who fulfilled the inclusion criteria and signed a 
written consent form were enrolled in the study. The 
research protocol was approved by Ethical Committee. The 
study was registered in Iranian Registry of Clinical Trials 
(registration number, 2013101214980). Inclusion criteria 
were age of 18-65 years and diagnosed with PDS according 
to ROME III criteria. The patients had at least one of the 
following symptoms occurring several times a week in 
the past 6 months: The discomfort feeling of postprandial 
fullness and/or early satiety. Exclusion criteria included 
pregnancy, breastfeeding, peptic ulcer, gastroesophageal 
reflux disease, dysphagia, celiac, GI surgery, irritable 
bowel syndrome, abdominal pain, night diarrhea, greasy 
or black stool, blood in stool, mental retardation, immune 
system disorders, major depression, bipolar disorder 
and psychosomatic disorders, severe recent weight loss, 
cancer, renal disorders, current use of antibiotics, proton 
pump inhibitors, H2 blockers, bismuth, metoclopramide, 
domperidone, lactulose, nonsteroid anti-inflammatory 
drugs, corticosteroids, herbal medicines and drug abuse. 
Patients who took <80% of administered medication or had 
drug intolerance were withdrawn from the study.
Subjects and intervention
Totally, 107 patients were enrolled in the study [Figure 1]. 
They were randomized by simple randomization method 
to blindly receive either anise or placebo for 4 weeks. 
Intervention group consisted of 47 patients and received 
anise powder, 3 gafter each meal (3 times/day). According 
to the Barnes et al.,[51] administration of up to 20 g/day anise 
powder is safe. The anise seeds were prepared by Barij 
Essence Pharmaceutical Company (MashhadArdehal, Iran) 
as a gift. This plant specimen was kept in their herbarium 
with number 1697.[52] Control group included 60 patients 
and received placebo powder, 3 g after each meal (3 times/
day). The latter included corn starch and were similar 
to anise package in shape, color, and size. Both powders 
were prepared in similar packages by Pharmacognosy 
Department of Isfahan School of Pharmacy at IUMS. One 
week medications were supplied to the patients at the 
beginning of the each week for 4 weeks. Both patients and 
doctors were blind to the treatments.
Instruments and outcomes
To evaluate the presence or absence of symptoms of FD, 
modified ROME III questionnaire,[3,53] was used. Its validity 
and reliability have been tested before.[54] The diagnosis of 
FD was based on the questionnaire filled out individually. 
To assess the severity of the disorder, FD severity scale was 
employed.[55] 4-item Likert scale (never or rarely, not very 
unpleasant, very unpleasant but tolerable, and can’t tolerate) 
was employed to answer the questions. Each participant’s 
total score was between 0 and 48. A detailed questionnaire 
was prepared to record the medication side effects too.
All patients were followed-up for 12 weeks. The primary 
and secondary endpoints were the mean score of severity 
of FD and the frequency distribution of patients with 
various severities across the study period, respectively. 
Assessments were carried out at baseline and at the end of 
weeks 2, 4 and 12.
Statistical analysis
Intention to treat analysis was used to avoid the bias associated 
with nonrandom loss of patients. Characteristics of the two 
groups were compared before and after intervention using 
Mann-Whitney U and Kruskal-Wallis tests for nonparametric 
variables and Student’s t-test for parametric variables. The 
changes from the baseline to the end of study period within 
Figure 1: Consort flowchart of the study
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Table 1: Comparison of mean (SD) scores of severity 
of FD within and between the two groups across 
the study period
Symptom/time FD severity score, mean (SD) Between 
groups
Anise, n = 47 Placebo, n = 60 P**
Epigastric discomfort
Baseline 0.47 (0.58) 0.50 (0.59) 0.80
Week 2 0.30 (0.55) 0.42 (0.56) 0.20
Week 4 0.09 (0.35) 0.40 (0.62) 0.001
Week 12 0.09 (0.35) 0.38 (0.66) 0.003
Within group 0.0001 0.02
P*
Early satiety
Baseline 0.92 (1.20) 0.93 (1.1) 0.90
Week 2 0.66 (0.94) 0.88 (1.1) 0.45
Week 4 0.30 (0.62) 0.90 (1.2) 0.008
Week 12 0.04 (0.20) 0.80 (1.2) 0.0001
Within group 0.0001 0.8
P*
Epigastric bloating
Baseline 0.74 (0.77) 0.55 (0.62) 0.20
Week 2 0.51 (0.72) 0.53 (0.67) 0.70
Week 4 0.15 (0.36) 0.58 (0.79) 0.001
Week 12 0.02 (0.14) 0.72 (0.95) 0.0001
Within group 0.0001 0.1
P*
Preprandial nausea
Baseline 0.04 (0.20) 0.03 (0.18) 0.80
Week 2 0.02 (0.14) 0.08 (0.42) 0.45
Week 4 0.02 (0.14) 0.08 (0.42) 0.45
Week 12 0.06 (0.32) 0.08 (0.42) 0.85
Within group 0.6 0.4
P*
Postprandial nausea
Baseline 0.04 (0.20) 0.07 (0.31) 0.85
Week 2 0.02 (0.14) 0.07 (0.31) 0.45
Week 4 0.06 (0.32) 0.05 (0.22) 0.90
Week 12 0.06 (0.32) 0.08 (0.42) 0.85
Within group 0.7 0.4
P*
Morning nausea
Baseline 0.02 (0.14) 0.03 (0.18) 0.70
Week 2 0.02 (0.14) 0.03 (0.18) 0.70
Week 4 0.02 (0.14) 0.03 (0.18) 0.70
Week 12 0.02 (0.14) 0.03 (0.18) 0.70
Within group 1.0 1.0
P*
Vomiting
Baseline 0.06 (0.24) 0.03 (0.18) 0.45
Week 2 0.06 (0.24) 0.08 (0.42) 0.80
Week 4 0.02 (0.14) 0.08 (0.42) 0.45
Week 12 0.02 (0.14) 0.08 (0.42) 0.45
Within group 0.1 0.4
P*
Retching
Baseline 0.02 (0.14) 0.08 (0.33) 0.25
Table 1: Contiuned
Symptom/time FD severity score, mean (SD) Between 
groups
Anise, n = 47 Placebo, n = 60 P**
Week 2 0.02 (0.14) 0.07 (0.25) 0.30
Week 4 0.06 (0.32) 0.07 (0.25) 0.65
Week 12 0.06 (0.32) 0.10 (0.43) 0.60
Within group 0.4 0.5
P*
Belching
Baseline 1.44 (0.83) 1.46 (0.85) 0.95
Week 2 0.87 (0.79) 2.05 (1.15) 0.0001
Week 4 0.21 (0.65) 2.28 (1.22) 0.0001
Week 12 0.10 (0.47) 2.13 (1.26) 0.0001
Within group 0.0001 0.0001
P*
Loss of appetite
Baseline 0.19 (0.45) 0.13 (0.43) 0.30
Week 2 0.19 (0.45) 0.13 (0.43) 0.20
Week 4 0.10 (0.31) 0.16 (0.58) 0.04
Week 12 0.02 (0.14) 0.17 (0.59) 0.02
Within group 0.001 0.5
P*
Epigastric fullness
Baseline 2.00 (0.95) 2.07 (0.84) 0.85
Week 2 1.25 (0.79) 2.23 (0.99) 0.0001
Week 4 0.34 (0.56) 2.21 (1.13) 0.0001
Week 12 0.10 (0.31) 2.18 (1.17) 0.0001
Within group 0.0001 0.03
P*
Epigastric pain
Baseline 1.76 (0.84) 1.81 (0.81) 0.80
Week 2 1.10 (0.84) 2.01 (0.99) 0.0001
Week 4 0.38 (0.70) 2.05 (1.18) 0.0001
Week 12 0.13 (0.39) 2.11 (1.19) 0.0001
Within group 0.0001 0.01
P*
Postprandial epigastric 
pain
Baseline 0.63 (0.82) 0.81 (0.83) 0.20
Week 2 0.55 (0.83) 1.05 (1.14) 0.02
Week 4 0.23 (0.63) 1.30 (1.33) 0.0001
Week 12 0.12 (0.49) 1.31 (1.42) 0.0001
Within group 0.0001 0.0001
P*
Preprandial epigastric 
pain
Baseline 0.29 (0.62) 0.41 (0.69) 0.30
Week 2 0.21 (0.50) 0.43 (0.81) 0.15
Week 4 0.10 (0.37) 0.53 (0.98) 0.008
Week 12 0.06 (0.24) 0.75 (1.15) 0.001
Within group 0.0001 0.03
P*
Night epigastric pain
Baseline 0.32 (0.59) 0.31 (0.53) 0.85
Week 2 0.29 (0.65) 0.35 (0.63) 0.45
Week 4 0.15 (0.55) 0.50 (0.96) 0.02
Week 12 0.12 (0.53) 0.65 (1.14) 0.004
(Continued)
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Table 1: Contiuned
Symptom/time FD severity score, mean (SD) Between 
groups
Anise, n = 47 Placebo, n = 60 P**
Within group 0.0001 0.02
P*
Epigastric burning
Baseline 1.59 (0.85) 1.70 (0.91) 0.55
Week 2 0.93 (0.64) 1.87 (1.19) 0.0001
Week 4 0.19 (0.39) 1.80 (1.33) 0.0001
Week 12 0.02 (0.14) 1.70 (1.42) 0.0001
Within group 0.0001 0.2
P*
Mean total score
Baseline 10.6 (4.1) 10.96 (4.1) 0.6
Week 2 7.04 (4.1) 12.30 (4.3) 0.0001
Week 4 2.44 (4.2) 13.05 (5.2) 0.0001
Week 12 1.08 (3.8) 13.30 (6.2) 0.0001
Within group 0.0001 0.0001
P*
*Friedman test was applied; **Mann-Whitney U-test was applied; SD = Standard 
deviation; FD = Functional dyspepsia
each group were tested using Friedman test and related 
samples Friedman’s two-way analysis of variance by ranks 
test. P < 0.05 were considered significant. Statistical Package 
for Social Sciences (SPSS Inc., Chicago, IL, USA), version 17 
for Windows was used to conduct statistical analysis.
RESULTS
Totally, 107 patients were enrolled in the study. Totally, 32 
(53.3%) and 21 (44.7%) females were included in the control 
and intervention groups, respectively. The difference was 
not significant (P = 0.3). The mean (standard deviation [SD]) 
age of patients in the control group was 41 (11.7) and in the 
intervention group was 45.5 (15.5) years (P = 0.1). Totally, 
34 (56.7%) and 32 (68%) patients had body mass index ≤25 
in the control and intervention groups, respectively (P = 
0.4).Totally, 47 (78.3%) patients in the control group and 
36 (76.6%) patients in the intervention group never smoked 
cigarettes (P = 0.9). Totally, 58 (96.7%) and 43 (91%) patients 
didn’t drink coffee in the control and intervention groups, 
respectively (P = 0.1). Four patients were withdrawn from 
the study in each group [Figure 1]. No serious medication 
side effect was reported in anise group.
Mean (SD) scores of 16 questions of FD severity scale 
in the two groups across the study period are shown in 
Table 1. Among all symptoms, epigastric fullness showed 
the highest severity and nausea demonstrated the lowest 
severity in both groups before the intervention [Table 1]. In 
other words, about 90% of patients had epigastric fullness 
whereas ≤5% suffered from nausea in both groups 
at baseline. The baseline mean scores of different FD 
symptoms were not significantly different between the two 
groups. After intervention, all symptoms were significantly 
different between the two groups at weeks 4 and 12, but 
retching, nausea and vomiting. Similarly, mean total scores 
of FD severity scale were not significantly different between 
the two groups before the intervention. But, they were 
significantly different between the two groups at weeks 2, 
4 and 12 [Table 1].
Mean severity scores of epigastric fullness, epigastric 
discomfort, epigastric burning/pain, early satiety, bloating, 
belching, and loss of appetite decreased significantly within 
anise group after intervention whereas only epigastric 
discomfort showed similar pattern within placebo group. 
On the other hand, mean severity scores of epigastric pain, 
epigastric fullness and belching increased significantly 
within the placebo group after intervention whereas no 
symptom revealed such an increasing score pattern within 
anise group [Table 1].
Distributions of the patients in different scales of severity of 
FD symptoms across the study period are demonstrated in 
Table 2. Similar to the mean severity scores, the distributions 
of patients before intervention were not significantly 
different between the two groups [Table 2]. Furthermore, the 
patterns of significance and nonsignificance of distributions 
of patients within each group and between the two groups 
were similar to those of the severity scores.
DISCUSSION
The current study demonstrated that anise was effective in 
the treatment of postpartum depression (PPD). Since the 
pathophysiology of FD is multifactorial and since anise has 
broad spectrum of pharmacological effects on GI, nervous, 
muscular and immune systems, it is not a surprise to see 
significant improvements of symptoms in patients with FD. 
The spasmolytic feature[50] of anise and its pain relieving 
character may explain the improvement of postprandial 
pain and epigastric discomfort. Antimicrobial effects[43] 
of anise against most bacteria may decrease or inhibit the 
activities of H. pylori in these patients. Inhibitory effects of 
anise on gastric mucosal damage[48] may decrease the micro-
inflammation of FD. The most important constituents of 
aniseeds essential oils responsible for the reported effects are 
trans-anethole, estragole, γ-hymachalen, p-anisaldehyde, 
and methyl chavicol.[56]
Some other herbs have also been investigated to find out 
their effectiveness on FD treatment with various results. 
The most famous ones were Iberogas (a herbal combination 
preparation, STW 5) which improved the symptoms of FD 
in 52-68% of cases and peppermint which was effective 
in 67-97% of patients.[57] Some of them have also been 
recognized to relieve bloating and intestinal gas. They are 
Ghoshegir, et al.: Pimpinella anisum in the treatment of FD
Journal of Research in Medical Sciences | January 2015 |17
Table 2: Distributions of the patients according to various degrees of severity of FD and comparison of distributions 
within and between the two groups across the study period
Symptom/
time
Anise (n = 47), number (%) Placebo (n = 60), number (%) Between 
groups
Never or 
rarely
Not very 
unpleasant
Very unpleasant 
but tolerable
Can’t 
tolerate
Never or 
rarely
Not very 
unpleasant
Very unpleasant 
but tolerable
Can’t 
tolerate
P**
Epigastric 
discomfort
Baseline 27 18 2 0 33 24 3 0 0.96
Week 2 35 10 2 0 37 21 2 0 0.30
Week 4 44 2 1 0 40 16 4 0 0.003
Week 12 44 2 1 0 42 14 3 1 0.02
Within group
P* 0.0001 0.02
Early satiety
Baseline 28 1 12 6 35 2 15 8 0.98
Week 2 28 10 6 3 35 4 14 7 0.08
Week 4 37 6 4 0 35 6 9 10 0.02
Week 12 45 2 0 0 39 4 7 10 0.001
Within group
P* 0.0001 0.85
Epigastric 
bloating
Baseline 21 17 9 0 31 25 4 0 0.15
Week 2 29 12 6 0 33 23 3 1 0.24
Week 4 40 7 0 0 34 19 5 2 0.009
Week 12 46 1 0 0 34 13 9 4 0.0001
Within group
P* 0.0001 0.1
Preprandial 
nausea
Baseline 45 2 0 0 58 2 0 0 0.8
Week 2 46 1 0 0 57 2 1 0 0.6
Week 4 45 1 1 0 57 2 0 1 0.5
Week 12 45 2 0 0 57 2 1 0 0.6
Within group
P* 0.6 0.4
Postprandial 
nausea
Baseline 45 2 0 0 57 2 1 0 0.6
Week 2 46 1 0 0 57 2 1 0 0.6
Week 4 45 1 1 0 57 3 0 0 0.4
Week 12 45 1 1 0 57 2 0 1 0.5
Within group
P* 0.7 0.4
Morning 
nausea
Baseline 46 1 0 0 58 2 0 0 0.7
Week 2 46 1 0 0 58 2 0 0 0.7
Week 4 46 1 0 0 58 2 0 0 0.7
Week 12 46 1 0 0 58 2 0 0 0.7
Within group
P* 1.0 1.0
Vomiting
Baseline 44 3 0 0 58 2 0 0 0.5
Week 2 44 3 0 0 57 2 1 0 0.5
Week 4 46 1 0 0 57 2 1 0 0.6
Week 12 46 1 0 0 57 2 1 0 0.6
(Continued)
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Table 2: Continued
Symptom/
time
Anise (n = 47), number (%) Placebo (n = 60), number (%) Between 
groups
Never or 
rarely
Not very 
unpleasant
Very unpleasant 
but tolerable
Can’t 
tolerate
Never or 
rarely
Not very 
unpleasant
Very unpleasant 
but tolerable
Can’t 
tolerate
P**
Within group
P* 0.1 0.4
Retching
Baseline 46 1 0 0 56 3 1 0 0.5
Week 2 46 1 0 0 56 4 0 0 0.3
Week 4 45 1 1 0 56 4 0 0 0.3
Week 12 45 1 1 0 56 3 0 1 0.5
Within group
P* 0.4 0.6
Belching
Baseline 9 9 28 1 11 13 33 3 0.9
Week 2 16 23 6 2 10 8 11 31 0.0001
Week 4 41 4 0 2 11 5 0 44 0.0001
Week 12 44 2 0 1 12 8 0 40 0.0001
Within group
P* 0.0001 0.0001
Loss of 
appetite
Baseline 39 7 1 0 54 4 2 0 0.4
Week 2 39 7 1 0 54 4 2 0 0.4
Week 4 42 5 0 0 54 4 0 2 0.4
Week 12 46 1 0 0 54 4 0 2 0.2
Within group
P* 0.001 0.5
Epigastric 
fullness
Baseline 5 6 20 16 5 4 33 18 0.5
Week 2 9 18 19 1 6 6 16 32 0.0001
Week 4 33 12 2 0 9 6 8 37 0.0001
Week 12 42 5 0 0 10 6 7 37 0.0001
Within group
P* 0.0001 0.03
Epigastric 
pain
Baseline 5 8 27 7 5 11 34 10 0.9
Week 2 10 26 7 4 6 11 19 24 0.0001
Week 4 34 9 3 1 10 10 7 33 0.0001
Week 12 42 4 1 0 10 9 5 36 0.0001
Within group
P* 0.0001 0.01
Postprandial 
epigastric 
pain
Baseline 26 13 7 1 25 23 10 2 0.5
Week 2 30 9 7 1 25 19 4 12 0.005
Week 4 40 4 2 1 25 13 1 21 0.0001
Week 12 43 3 0 1 29 7 2 22 0.0001
Within group
P* 0.0001 0.0001
Preprandial 
epigastric 
pain
Baseline 37 6 4 0 42 11 7 0 0.6
(Continued)
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Table 2: Continued
Symptom/
time
Anise (n = 47), number (%) Placebo (n = 60), number (%) Between 
groups
Never or 
rarely
Not very 
unpleasant
Very unpleasant 
but tolerable
Can’t 
tolerate
Never or 
rarely
Not very 
unpleasant
Very unpleasant 
but tolerable
Can’t 
tolerate
P**
Week 2 39 6 2 0 43 11 3 3 0.3
Week 4 43 3 1 0 43 8 3 6 0.05
Week 12 44 3 0 0 39 7 4 10 0.002
Within group
P* 0.0001 0.03
Night 
epigastric 
pain
Baseline 35 9 3 0 43 15 2 0 0.6
Week 2 37 7 2 1 43 14 2 1 0.7
Week 4 43 2 1 1 44 8 2 6 0.1
Week 12 44 1 1 1 43 5 2 10 0.03
Within group
P* 0.0001 0.02
Epigastric 
burning
Baseline 9 3 33 2 9 9 33 9 0.1
Week 2 11 28 8 0 12 11 10 27 0.0001
Week 4 38 9 0 0 17 9 3 31 0.0001
Week 12 46 1 0 0 22 5 2 31 0.0001
Within group
P* 0.0001 0.2
*Test of related samples Friedman’s two-way analysis of variance by ranks was applied; **Chi-square test was applied; FD = Functional dyspepsia
called carminatives. Anise, peppermint, and cinnamon are 
the prototypes of these herbs but few clinical trials have 
been carried out to show the evidence.[58] This was the first 
randomized clinical trial assessing the therapeutic effects of 
anise on patients with FD. But, this study had the following 
limitations. First, it was conducted in a single center. Thus, 
the study population was homogenous which limited the 
external validity of the results. Second, the sample size 
was small, and the follow-up period was relatively short. 
It is suggested to include larger numbers of patients with 
longer periods of follow-up in multiple centers in the future 
investigations.
CONCLUSIONS
Anise was effective and tolerable in the relieving the 
symptoms of PPD. These effects were observed even 8 weeks 
after discontinuation of anise administration.
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